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http:WHAT THIS PAPER ADDS
Pre-interventional statin medication shows a beneﬁt in carotid artery stenosis patients treated with endarter-
ectomy; however, there are few data available on patients treated with stent-angioplasty. This study shows that
pre-interventional statin medication has a signiﬁcant protective effect against peri-interventional stroke,
myocardial infarction, or death (composite endpoint) in patients with internal carotid artery stenosis treated
with stent-angioplasty. Accordingly, statins could be considered as a standard pre-interventional medical therapy
in connection with carotid stenting.Background: In primary and secondary prevention, statins signiﬁcantly reduce cardiovascular and
cerebrovascular events. Pre-interventional statin medication shows a beneﬁt in carotid artery stenosis patients
treated with endarterectomy; however, there are few data available for patients treated with stent-angioplasty.
The aim of this study was to investigate whether pre-interventional statin therapy is associated with decreased
peri-interventional risk of stroke, myocardial infarction, and mortality in patients undergoing stent-angioplasty for
internal carotid stenosis.
Methods: Data for 344 consecutively documented patients with internal carotid artery stenosis treated with
stent-angioplasty in the years 2002e2012 at the same stroke center were collected in a prospectively deﬁned
database. Risk factors, medication, and indication for therapy were documented. Univariate and multivariate
analysis was performed to investigate independent reduction of peri-interventional stroke, myocardial infarction,
or death by statin medication prior to stent-angioplasty.
Results: The median age was 70 years (p25: 63, p75: 76), 75.5% of patients were male, and the median stenosis
was 85% according to ECST criteria (p25: 80%, p75: 90%). 20.1% of patients had asymptomatic stenoses, and
60.2% had statin medication before stenting. As per multivariate analysis, pre-interventional statin medication
was a predictor for signiﬁcant peri-interventional risk reduction regarding primary endpoint ischemic stroke,
myocardial infarction (MI), or death (odds ratio (OR) 0.31, p ¼ .006). Statins also had a signiﬁcant protective
effect in secondary endpoint ischemic stroke, intracranial bleeding or death (OR 0.39, p ¼ .014), and ischemic
stroke or myocardial infarction (OR 0.20; p ¼ .002).
Conclusions: This study shows that pre-interventional statin medication has a protective effect against peri-
interventional stroke, MI, or death in patients with internal carotid artery stenosis treated with stent-angioplasty.
Accordingly, statins could be considered as a standard pre-interventional medical therapy in carotid stenting.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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complicationsBACKGROUND AND PURPOSE
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) are part of the best available medical treatment for
patients with atherosclerotic stenosis, and reduce the inci-
dence of stroke and myocardial infarction.1e5 The anti-
atherosclerotic effect of statins not only correlates with theresponding author. T. Reiff, Department of Neurology, University of
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//dx.doi.org/10.1016/j.ejvs.2014.08.010decrease in low-density lipoprotein (LDL) cholesterol, but
they also have beneﬁcial pleiotropic effects beyond their
hypolipidemic action.6 In patients with atherosclerotic ste-
noses treated by carotid endarterectomy (CEA) or percuta-
neous coronary intervention, the peri-procedural risk of
stroke, myocardial infarction, and death is lowered by pre-
procedural treatment with statins.7e9 Relevant mecha-
nisms may be effects on platelet adhesion, reduction of
thrombosis, improved endothelial cell function, upregulation
of endothelial nitric oxide synthase, plaque stability,
decreased vascular smooth muscle cell proliferation and
migration, and neuroprotection and modulation of inﬂam-
mation.10e20 Stent-angioplasty is increasingly used as an
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supplying the brain. Stent-angioplasty induced effects such as
platelet activation, thrombosis, and inﬂammatory processes
within the vessel wall appear to be attenuated by statins.21,22
Accordingly, peri-interventional risk reduction in stenting is
an essential issue, and the beneﬁt of statin use before
stenting has to be evaluated, not least because little evidence
is available currently for peri-procedural drug therapy in ca-
rotid artery stenting.23 The aim of this study was to investi-
gate the effect of pre-procedural statinmedication on the risk
of peri-procedural stroke, myocardial infarction, and mor-
tality in a set of patients at a specialized center treated with
stent-angioplasty for extracranial carotid stenoses.METHODS
The study included all patients treated for the ﬁrst time
with stent-angioplasty for internal carotid artery stenosis
from 1/2002 to 9/2012. Data were consecutively collected
in a database of all patients with extracranial and intra-
cranial stenosis treated with stent-angioplasty at the au-
thors’ stroke center. Procedures involving intracranial
vessels and the stenting of recurrent stenosis in the same
patient were excluded. To achieve a homogenous group of
patients for this study, stenting of other extracranial vessels
such as the common carotid, subclavian, vertebral, or bra-
chiocephalic trunk, was excluded from the analysis.
Indication for treatment (asymptomatic stenosis, tran-
sient monocular blindness, TIA, minor stroke or major
stroke) as well as patients’ pre-treatment condition
including risk factors (arterial hypertension, diabetes mel-
litus, hyperlipidemia, nicotine abuse, coronary artery dis-
ease), lipometabolism parameters, medication (including
statin and dose), time span between neurological symptoms
and stenting in symptomatic patients, and details of pro-
cedure (including type of stent) were documented. All
variables in the database were deﬁned prospectively.
At the authors’ center, patients with moderate to severe
(>70%ECST ¼ >50%NASCET) carotid artery stenosis are
treated invasively if this stenosis had caused neurological
symptoms within the previous 6 months or e in asymp-
tomatic patients e if there are indications for an increased
risk of stroke (e.g. rapidly progressive stenosis, micro-
emboli).24 Some patients with asymptomatic stenosis were
treated within the SPACE-2-study. Patients are treated with
stenting instead of endarterectomy if a) the stenosis is not
accessible to vascular surgery, b) there is increased peri-
operative risk, c) in case of pre-treatment by vascular sur-
gery or following radiotherapy, d) within a randomized
clinical trial, e) in accordance with patient preference, and f)
in combination with intracranial thrombectomy in acute
stroke patients. Exclusion criteria for stenting were stenosis
inaccessibility as a result of aortic arch anatomy or severe
atherosclerosis, severe renal insufﬁciency (creatinine
>2.0 mg/dL, glomerular ﬁltration rate <30 mL/min), and
severe allergies to aspirin, clopidogrel, or contrast media
(anaphylactic reactions). Stenosis assessment at baseline
(degree of stenosis and characteristics) was performed byduplex ultrasound, optionally supplemented with contrast-
enhanced CT/MRI or digital subtraction angiography. Ul-
trasound stenosis graduation was performed in accordance
with DEGUM ultrasound criteria for grading internal carotid
artery stenoses.25 During the stenting procedure, the de-
gree of stenosis was re-evaluated angiographically, and
treatment was undertaken only if moderate to severe ste-
nosis was conﬁrmed.
All patients were premedicated with ASA 100 mg and
clopidogrel 75 mg for at least 3 days prior to stenting.
Alternatively for clopidogrel, a loading dose of 300e600 mg
was administered 1 day prior to stent-angioplasty. Acute
ischemic stroke patients undergoing emergency stenting
were treated with tiroﬁban in the ﬁrst 12 hours after
intervention. Subsequently, loading doses of ASA and clo-
pidogrel were administered. Prior to stenting, all patients
gave informed consent. All stenting procedures were per-
formed by experienced interventional neuroradiologists.
Stenting was performed without cerebral protection devices
(CPD). After stenting all patients were monitored at the
stroke unit, undergoing examinations every 6 hours by
experienced stroke physicians. Patients with new clinical
symptoms during or post-intervention were re-evaluated
with CT or MRI to establish whether a new ischemic
stroke or an intracranial hemorrhage had occurred.
Deﬁnitions
Symptomatic artery stenosis was deﬁned as neurological
symptoms associated with stenosis lasting 24 hours (TIA) or
longer (stroke) within the 6 months prior to stenting. TIA
was deﬁned as any neurological deﬁcit (including transient
monocular blindness) lasting no longer than 24 hours. Any
neurological deﬁcit persisting for longer than 24 hours and
increasing the NIHSS by 4 points or less was classiﬁed as a
minor stroke, whereas any neurological deﬁcit persisting for
longer than 30 days and related to an increase of NIHSS by
more than 4 points was classiﬁed as a major stroke. A
myocardial infarction was deﬁned by a rise in cardiac bio-
markers (preferably troponin) by at least one value above
the 99th percentile of the upper reference limit and evi-
dence of myocardial ischemia with at least one symptom
of ischemia (ECG changes indicative of new ischemia, new
ST/T changes or new left-bundle branch block, new onset of
pathological Q-waves in ECG, imaging evidence of new loss
of viable myocardium, or new regional wall motion
abnormality).
Complications and endpoints
Complications after stent-angioplasty, such as TIA, stroke,
myocardial infarction prior to discharge, or death were
analyzed with regard to pre-interventional statin medica-
tion. In the case of death, the most likely reason was also
documented. Affecting mostly the long-term outcome, pri-
mary endpoint was deﬁned as a composite of the main
severe risks in patients with systemic atherosclerosis:
ischemic stroke, myocardial infarction, and death. As a
secondary endpoint a composite of ischemic stroke and
Table 1. Baseline characteristics extracranial stenting, n ¼ 344.
Characteristics Age [median, p25, p75] 70 63, 76
Sex (male) [n, %] 261 75.9
Stenosis Grade of stenosis%ECST
[median, p25, p75]
87.5 80, 90
Side: left [n, %] 181 52.6
Risk factors Arterial hypertension [n, %] 291 84.6
Diabetes mellitus [n, %] 96 27.9
Present smoker [n, %] 84 24.4
Hypercholesterolemia [n, %] 229 66.6
Coronary artery
disease [n, %]
134 39.0
Pre-treatment
medication
Antihypertensive
medication [n, %]
249 72.4
Statin medication [n, %] 207 60.2
Indication
for therapy
Asymptomatic [n, %] 69 20.1
Transient monocular
blindness [n, %]
32 9.3
TIA [n, %] 81 23.5
Minor stroke [n, %] 110 32.0
Major stroke [n, %] 52 15.1
628 T. Reiff et al.death was deﬁned. Because the combination of ASA and
clopidogrel before stenting, tiroﬁban in emergency stenting,
and vulnerable brain tissue elevate intracranial bleeding
complication risks, composite secondary endpoints were
intracranial bleeding and stroke, and stroke, intracranial
bleeding, and death. Details of cases of intracranial bleeding
were recorded (side, localization, reason).
Statistics
Univariate analysis was performed on patients with pre-
procedural statins compared with patients with no statins
before the stenting procedure. Statistical testing methods
were ManneWhitney U test, chi-square test, and odds ratio
with 95% conﬁdence intervals. When expected cell fre-
quency was <5, the Fisher Exact test was used. Adjustment
for confounding factors was performed by multivariate lo-
gistic regression analysis for all endpoints. The multivariate
analysis encompassed the independent variables age, sex,
arterial hypertension, diabetes, smoker, hypercholesterole-
mia, statin medication, coronary heart disease, and tiroﬁban
medication in a stepwise logistic regression model. Any p
values larger than .10 were removed. To strengthen multi-
variate analysis, only those indications for therapy or lab-
oratory values signiﬁcantly correlated (p  .05) with any
endpoint in univariate analysis were used in the multivar-
iate logistic regression model. Statistical analysis was per-
formed using STATA-IC 12.
The study was approved by the local ethics committee.
RESULTS
Consecutive patients (344) with moderate to high-grade
stenosis of the internal carotid artery and treated with
stent-angioplasty were selected from the database. The
majority of patients were male (76%), and the median age
was 70 years (p25: 63; p75: 76 years). Most patients had
high-grade stenosis (median 87.5% ECST; p25: 80%; p75
90%). In 20%, the indication for interventional therapy was
asymptomatic stenosis, and in 80% symptomatic stenosis
(mainly TIA and minor stroke). The main vascular risk factors
were arterial hypertension (85%), hypercholesterolemia
(67%), coronary artery disease (39%), diabetes mellitus
(28%), and smoking (24%). Prior to the stenting procedure,
72% of the patients were on antihypertensives, and 60%
were on statins. 49% were treated within 7 days of symp-
tom onset, 7% had emergency stenting (<24 hours after
symptom onset) (for further details, see Table 1). For details
of statin medication and stents used, see Tables S1 and S2
(supplementary material). Of patients on statin medication,
91% had hypercholesterolemia, whereas 9% received statins
because of atherosclerotic changes in the coronary/carotid
arteries. Of the patients without statins, 30% had hyper-
cholesterolemia, 95% of these were stented in emergency
situations involving symptomatic stenosis.
Lipid parameters
Patients with statin medication had signiﬁcantly lower total
cholesterol levels (175 mg/dL (p25: 152; p75: 212) vs.196 mg/dL (p25: 170; p75: 224); ManneWhitney U test:
p ¼ .001) and LDL-cholesterol (99 mg/dL (p25: 78; p75: 127)
vs. 119 mg/d: (p25: 103; p75: 144); ManneWhitney U test:
p ¼ .000). There was no signiﬁcant effect on triglycerides.
In logistic regression analysis there was no signiﬁcant effect
of cholesterol, LDL-cholesterol, or triglycerides on any
endpoint.
Tiroﬁban
Patients treated with tiroﬁban (n ¼ 19) because of emer-
gency stenting had signiﬁcantly more intracerebral bleeding
complications (n ¼ 4; p ¼ .000) and non-signiﬁcantly sub-
arachnoid hemorrhage (n ¼ 1; p ¼ .108). All of these pa-
tients had undergone successful stenting. Two patients
(0.6%) had tiroﬁban without ASA or clopidogrel before
stenting. These patients had a signiﬁcantly elevated
bleeding risk but no signiﬁcantly elevated ischemic stroke
risk (for details see Table S3, supplementary material).
Intracerebral bleeding complications
All non-fatal intracranial bleeds (n ¼ 7) were ipsilateral. Two
of these were space occupying with ventricular hemor-
rhage, one was related to hyperperfusion syndrome, two
patients had hemorrhage in the infarct area, and two pa-
tients had subarachnoid hemorrhage.
Age and sex did not differ signiﬁcantly between the pa-
tient groups treated with or without statins. In the statin
group, vascular risk factors were more frequent. There was
a signiﬁcant difference for arterial hypertension, hyper-
cholesterolemia, coronary artery disease, cholesterol, and
LDL-cholesterol. No signiﬁcant difference was found for
severity or side of stenosis. Signiﬁcantly more patients with
statins had asymptomatic stenosis and minor strokes,
whereas fewer had stroke as an indication for stenting (for
details, see Table 2).
Table 2. Patients with and without pre-interventional statin medication: baseline characteristics.
Statin use No statin use p
n ¼ 207 n ¼ 137
Characteristics Age (median) 70 63, 76c 70 61.5, 77.5c 0.802a
Sex (male) 160 77.3% 101 73.7% 0.448b
Risk factors Arterial hypertension 183 88.4% 108 78.8% 0.023b
Diabetes 65 31.4% 31 22.6% 0.097b
Smoker 49 23.7% 35 25.5% 0.768b
Hypercholesterolemia 188 90.8% 41 29.9% 0.000b
Coronary heart disease 100 48.3% 34 24.8% 0.000b
Total cholesterol (mg/dl) 175 152, 212.5c 196 170, 224c 0.001a
LDL-cholesterol (mg/dl) 99 78, 127c 119 102.5, 144c 0.000a
HDL-cholesterol (mg/dl) 42 32.25, 49c 40.5 33, 51c 0.434a
Triglycerides (mg/dl) 138 101, 204c 133 96.5, 174.5c 0.375a
Stenosis Severity (median ECST) 85% 80%, 90%c 90% 80%, 90%c 0.401a
Left side 109 52.7% 72 52.6% 0.985b
Indication Asymptomatic 57 27.5% 12 8.8% 0.000b
Transient monocular blindness 22 10.6% 10 7.3% 0.298b
TIA 49 23.7% 32 23.4% 0.946b
Minor stroke 56 27.1% 54 39.4% 0.016b
Major stroke 23 11.1% 29 21.2% 0.011b
a ManneWhitney U test.
b Chi-square.
c Lower quartile, upper quartile.
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Nineteen patients (5.5%) had a peri-interventional TIA, 28
(8.1%) had ischemic strokes (22 ipsilateral, 6 bilateral, 0 only
contralateral), one (0.3%) had a myocardial infarction, and
four (1.2%) patients died. Patients with statins had fewer
ischemic strokes, less subarachnoid hemorrhage, less
myocardial infarction, and fewer fatal outcomes, although
the differences were not signiﬁcant (for details see Table 3).
In univariate analysis, no indication for stenting or any
laboratory value was signiﬁcantly (p  .05) correlated with
any endpoint (data not shown), thus no indication forTable 3. Peri-interventional complications and endpoints with and
without pre-interventional statin medication (univariate analysis).
Statin use No statin use p
n ¼ 207 n ¼ 137
TIA 10 4.8% 9 6.6% 0.490b
Ischemic stroke 13 6.3% 15 10.9% 0.121b
Minor stroke 8 3.9% 11 8.0% 0.098b
Major stroke 5 2.4% 4 2.9% 0.745a
ICB 3 1.4% 2 1.5% 1.000a
SAB 0 0.0% 2 1.5% 0.158a
Myocardial infarction 0 0.0% 1 0.7% 0.398a
Death 1 0.5% 3 2.2% 0.305a
Ischemic stroke, MI,
death
14 6.8% 19 13.9% 0.028b
Ischemic stroke, MI 13 6.3% 16 11.7% 0.078b
Ischemic stroke, ICH 16 7.7% 19 13.9% 0.065b
Ischemic stroke, ICH,
death
17 8.2% 22 16.1% 0.025b
TIA ¼ transient ischemic attack; ICB ¼ intracerebral bleeding;
SAB ¼ subarachnoid hemorrhage; MI ¼ myocardial infarction;
ICH ¼ intracranial hemorrhage.
a Fisher’s Exact test.
b Chi square test.stenting or any laboratory value was included in multivar-
iate analysis. Analyzing patients with asymptomatic versus
symptomatic stenosis showed no signiﬁcant difference
regarding peri-procedural stroke, TIA, myocardial infarction,
or death. The median time between neurological symptoms
and stenting in symptomatic patients was 10 days (p25: 5,
p75: 20) and did not signiﬁcantly correlate with any
endpoint. Thirty-six patients received a clopidogrel loading
dose 300 mg before stenting. In univariate analysis there
was no signiﬁcant correlation with any endpoint. Also, no
stent type had a signiﬁcant correlation with any endpoint in
univariate analysis.
Primary endpoint events occurred in 33 patients (9.6%).
After adjustment for age, sex, tiroﬁban medication, and risk
factors, statin medication before stenting remained the only
independent variable with a signiﬁcant protective effect
related to the primary endpoints of ischemic stroke,
myocardial infarction (MI), and death (OR 0.31, p ¼ .006)
and the secondary endpoints ischemic stroke and MI (OR
0.20, p ¼ .002), ischemic stroke and intracranial hemor-
rhage (OR 0.38, p ¼ .024), and ischemic stroke, intracranial
hemorrhage, and death (OR 0.37, p ¼ .016). Coronary heart
disease was a non-signiﬁcant risk factor for primary
endpoint and all secondary endpoints. Tiroﬁban was
signiﬁcantly correlated with elevated bleeding risk in sec-
ondary endpoint ischemic stroke and ICH (OR 4.35,
p ¼ .026) and secondary endpoint ischemic stroke, ICH, and
death (OR 5.57, p¼ .006). Hypercholesterolemia was a non-
signiﬁcant risk factor for secondary endpoint ischemic
stroke or MI (for details, see Table 4).
DISCUSSION
Statin use prior to stent-angioplasty showed a signiﬁcant
preventive effect both for the primary endpoint as a
Table 4. Multivariate analysis for endpoints.
Endpoint n % Signiﬁcant variables OR p 95% CI
Ischemic stroke, MI, death 33 9.6% Statin medication 0.31 0.006 0.13 0.71
CHD 2.13 0.078 0.92 4.92
Ischemic stroke, MI 29 8.4% Statin medication 0.20 0.002 0.07 0.55
CHD 2.22 0.079 0.91 5.40
Hypercholesterolemia 2.49 0.099 0.84 7.38
Ischemic stroke, ICH 35 10.2% Statin medication 0.38 0.024 0.16 0.88
CHD 2.07 0.091 0.89 4.82
Tiroﬁban 4.35 0.026 1.19 15.92
Ischemic stroke, ICH, death 39 11.3% Statin medication 0.37 0.016 0.16 0.83
CHD 1.99 0.097 0.88 4.50
Tiroﬁban 5.57 0.006 1.62 19.13
MI ¼ myocardial infarction; ICH ¼ intracranial hemorrhage; CHD ¼ coronary heart disease; OR ¼ odds ratio.
630 T. Reiff et al.combination of peri-interventional ischemic stroke,
myocardial infarction, and death, and for secondary end-
points including intracranial hemorrhage and mortality. It
needs to be noted, however, that the baseline characteris-
tics differed signiﬁcantly in both groups. On the one hand,
patients in the statin group displayed signiﬁcantly higher
vascular risk factors and co-morbidities that may have
increased their risk of stroke, MI, or death. On the other
hand, these patients may have proﬁted from regular med-
ical examinations and better medical prevention regimes.
Furthermore, in the statin group stent-angioplasty was
more frequently performed in cases of asymptomatic ste-
nosis. Assuming a higher interventional risk level for stent-
angioplasty for symptomatic stenosis, this baseline imbal-
ance may be relevant. Nonetheless, multivariate analysis
including all these factors conﬁrmed the role of statin
medication as a signiﬁcant protective factor against peri-
interventional complications in carotid stenting. Although
statin use was reported to be related to increased risk of
cerebral hemorrhage,26 increased rates of clinically relevant
post-procedural intracranial bleeding were not observed in
the statin group. This observation is supported by the
ﬁnding that statin use does not correlate with higher
mortality or intracranial bleeding rates in patients with
acute ischemic stroke even if they have undergone throm-
bolytic therapy.27 Patients having emergency stenting pro-
cedures because of acute ischemic stroke and without
premedication with platelet inhibitors received tiroﬁban
and had a higher risk of intracranial bleeding complications.
In all of these patients recanalization was achieved.
The results of the study are similar to the known risk
reducing effect of statin therapy in patients undergoing
carotid endarterectomy,7,8 and are congruent with the data
published regarding the relationship between risk reduction
in stenting and pre-interventional statin medication.28e30 In
both CEA and stent-angioplasty, statins appear to prevent
embolic complications through their pleiotropic effects such
as plaque stabilization and the reduction of intravascular
thrombosis. Prevention of embolic events is an important
issue, especially in carotid artery stenting as it has been
shown to generate more cerebrovascular lesions than
CEA.31 The preventive effect of statins is corroborated by
studies showing statin use being associated with reduced
plaque volume and atheroma regression in the carotidcirculation,32 as well as less embolic debris during carotid
artery stenting.33 That there are higher rates of peri-
interventional strokes in this study in comparison with
previously published data28 may be associated with the
much higher percentage of symptomatic patients in this
analysis. The present study population reﬂects the medical
routine at a specialized stroke center, including high risk
patients with multiple morbidity sent from surrounding
hospitals for emergency treatment. The peri-procedural
complication rate correlates with the 9.4% risk of stroke
or death (not including MI) in patients undergoing CAS
within 7 days from the qualifying event.34
In comparison with the published data of symptomatic
patients only,29 the present study had a similar complication
rate, conﬁrming the protective beneﬁt of pre-interventional
statin medication for the larger group of patients in this
investigation. To achieve generalization of these results for
all patients treated with stent-angioplasty, both symptom-
atic and asymptomatic patients were included in the anal-
ysis. Furthermore, patients with clinically asymptomatic
stenoses may also have plaque instability, and these pa-
tients will beneﬁt from statin treatment. In this study, sta-
tins showed LDL-cholesterol lowering effects; however,
considering the impact of other multiple pleiotropic effects
caused by statins, such as effects on endothelial function,
inﬂammation, arterial myocyte proliferation, migration and
apoptosis, plaque stability, platelet activity, and the coagu-
lation process, the lowering of LDL-cholesterol is not the
only relevant parameter for the achievement of successful
risk reduction.11,35 As in other studies, LDL-cholesterol
levels did not show a signiﬁcant effect on any endpoint.
Results of various studies suggest that treatment with sta-
tins should be indicated in accordance with the global
vascular risk proﬁle and not primarily on base-level LDL-
cholesterol concentrations.36,37 The limitations of this study
are the retrospective analysis of prospectively collected
data with lower impact than randomized comparison. The
potentially protective effects of the long term use of statins
prior to stent-angioplasty remain elusive, because the pre-
cise duration of their use before the stenting procedure was
not documented prospectively and thus could not be
included in this analysis. Plaque morphology as an impor-
tant co-factor of peri-interventional stroke risk was not
stringently documented and, therefore, could not be
Statins Reduce in Carotid Stenting 631included in statistical analysis. As stent-angioplasty is
frequently performed with CDP, CAS treatment without CPD
in this study is another limit. Thus a direct transfer of the
present results to patients treated with CPD may be
restricted. However, placement of CPD systems is also
suspected to cause embolic brain lesions. So statin associ-
ated plaque stabilization would be beneﬁcial when using
CPD too. With reference to potential gender speciﬁc effects
of statins, the small proportion of female patients in this
study is another limitation.
In summary, the present study demonstrates that the
reduction of the risk of peri-interventional stroke, MI, and
death in stent-angioplasty patients receiving statin pre-
medication is similar to the peri-procedural risk reduction
in patients treated with endarterectomy. These results are
congruent with other published data and provide an op-
portunity not only to reduce the side effects of treatment
but also to cut down on hospitalization rates and costs.38
Hence statins should be part of best practice pre-
interventional medical treatment for atherosclerotic ste-
noses of arteries supplying the brain, not only in connection
with endarterectomy but also with stent-angioplasty.
Conclusion
Pre-interventional statin medication signiﬁcantly reduced
the risk of stroke, myocardial infarction, or death following
stent-angioplasty of the carotid arteries. Comparable with
the therapy regimen for carotid endarterectomy, pre-
treatment with statins appears to be effective in reducing
peri-interventional complications in patients treated with
stent-angioplasty.
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